Compare Hormel Foods Corp (HRL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Hormel Foods Corp trades at $20.09 (market cap $10.57B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Hormel Foods Corp is far larger — about 2.1× Travere Therapeutics Inc. Common Stock's market cap, and Hormel Foods Corp pays a 6.09% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HRL | TVTX | |
|---|---|---|
Market Cap | $10.57B | $5.02B |
Volume | 4,381,202 | 2,060,842 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $67.52 |
52-Week Low | $19.19 | $26.79 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $12.56B | $5.15B |
Dividend Yield | 6.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.21, down 0.47% with a bearish technical outlook. The stock shows mixed fundamentals with declining net margins (2.82% in 2026) but consistent earnings beats and a $1.06B Brakebush acquisition to expand foodservice presence. Valuation metrics include a P/E of 30.98 and P/S of 0.87, while analyst consensus is cautious with 20% buy ratings.
Investment outlook balances dividend stability (60-year growth streak) against margin pressures and acquisition integration risks. The consensus price target of $25 offers 30% upside, but weak technicals and shrinking dividend raises warrant caution. Key catalysts include Brakebush synergies and foodservice growth execution.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
